Show simple item record

dc.contributor.authorAvery, Lisa M.
dc.contributor.authorSteed, Molly E.
dc.contributor.authorWoodruff, Ashley E.
dc.contributor.authorHasan, Muhammad
dc.contributor.authorRybak, Michael J.
dc.date.accessioned2015-05-05T20:59:28Z
dc.date.available2015-05-05T20:59:28Z
dc.date.issued2012-11
dc.identifier.citationAvery et. al. "Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole." Antimicrob. Agents Chemother. November 2012 vol. 56 no. 11 5990-5993

http://dx.doi.org/10.1128/AAC.01046-12
en_US
dc.identifier.urihttp://hdl.handle.net/1808/17607
dc.description.abstractWe report two cases of daptomycin (DAP)-nonsusceptible (DNS) vancomycin-intermediate Staphylococcus aureus (VISA) vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazole. Both patients responded rapidly and favorably to this combination. The clinical isolates from the two patients were tested post hoc in an in vitro pharmacokinetic/pharmacodynamic (PK/PD) model to confirm the bactericidal activity and enhancement of daptomycin and trimethoprim-sulfamethoxazole. The combination of high-dose daptomycin and trimethoprim-sulfamethoxazole should be explored further for the treatment of DNS VISA strains.en_US
dc.description.sponsorshipM.J.R. has received grant support, consulted for, or provided lectures for Astellas, Cubist, Forest, Clinical Therapeutics, Theravance, and Rib- X. L.M.A has served as an advisory board member (Forest) and provided lectures (Astellas) and owns stock (Merck). M.E.S., A.E.W., and M.H. have no potential conflicts of interest.en_US
dc.publisherAmerican Society for Microbiologyen_US
dc.titleDaptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazoleen_US
dc.typeArticle
kusw.kuauthorSteed, Molly E.
kusw.kudepartmentDepartment of Pharmaceutical Chemistryen_US
dc.identifier.doi10.1128/AAC.01046-12
kusw.oaversionScholarly/refereed, publisher version
kusw.oapolicyThis item meets KU Open Access policy criteria.
dc.rights.accessrightsopenAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record